.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
E7820 represents a significant advancement in targeted cancer therapy. Researchers initially developed this sulfonamide-type agent to inhibit angiogenesis by suppressing integrin α2 expression. However, subsequent discoveries repositioned E7820 as a potent molecular glue degrader. Specifically, the drug promotes the degradation of the splicing factor RBM39 through the DCAF15 E3 ligase complex. This mechanism provides a novel rationale for clinical evaluation in solid tumors where traditional inhibitors often fail.
The discovery of molecular glue degraders has transformed the landscape of oncology. Unlike traditional drugs that occupy a binding pocket, these agents induce proximity between a target protein and a ubiquitin ligase. Consequently, the cellular machinery degrades the disease-causing protein. In the case of E7820, targeting RBM39 leads to global RNA splicing defects. This process is particularly lethal to cancer cells that rely on specific splicing pathways for survival.
Furthermore, preclinical screening using patient-derived xenograft (PDX) models showed high activity in specific cancers. These include biliary tract and endometrial cancers, particularly those with homologous recombination repair (HRR) gene alterations like BRCA1, BRCA2, or ATM. Therefore, clinicians believe that E7820 might be highly effective when targeted at these specific molecular signatures.
The multicenter investigator-initiated phase I CIRCUS trial is currently underway in Japan. This study evaluates the safety, tolerability, and preliminary efficacy of E7820 in patients with unresectable solid tumors. Investigators previously established 100 mg/day as the maximum tolerated dose in early trials. Nevertheless, those studies observed no objective responses because they lacked biomarker-driven selection. By focusing on patients with HRR gene alterations, this trial seeks to demonstrate proof of concept for the drug.
Overall, this research highlights the importance of drug repositioning. Additionally, it offers a pathway for developing compounds that previously appeared intractable. If successful, the CIRCUS trial will provide a new treatment option for patients with difficult-to-treat solid malignancies.
E7820 acts by recruiting the splicing factor RBM39 to the DCAF15 E3 ubiquitin ligase. This interaction leads to the proteasomal degradation of RBM39, causing widespread splicing errors and cancer cell death.
The trial focuses on Japanese patients with unresectable solid tumors. Specifically, it explores efficacy in biliary tract cancer, endometrial cancer, and tumors harboring homologous recombination repair (HRR) gene mutations.
While E7820 was originally an anti-angiogenesis drug, its discovery as a molecular glue degrader provided a more powerful therapeutic rationale. Preclinical PDX models showed significant tumor shrinkage in biomarker-defined cohorts, justifying the current phase I trial.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
1. Okada M et al. Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303). Jpn J Clin Oncol. 2026 Mar 01. doi: undefined. PMID: 41764635.
2. Uehara T, et al. Selective degradation of splicing factor RBM39 by an antitumor sulfonamide and its role in cancer cell survival. Nat Commun. 2017;8:1582.
3. Eisai. Investigator-initiated clinical studies of E7820 launched following J-PDX confirmation of tumor shrinkage. News Release. 2024.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The CIRCUS trial evaluates E7820, a molecular glue degrader targeting RBM39, in Japanese patients with solid tumors including biliary and endometrial cancer...
6 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
Explore real-world data showing how private oncogenetics and molecular tumor boards achieve 3-week consult turnaround, high ctDNA actionability, and vital germline variant detection, enhancing individualized cancer care and familial risk assessment.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
